# US 2015/0148353 A1 · Oxabicycloheptanes and oxabicycloheptenes for the treatment of diabetes

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0148353 A1
- Document ID: US20150148353A1
- Status: Published application
- Kind: A1
- Application number: 14/408,475
- Filed: 2013-06-28
- Published: 2015-05-28
- Earliest claimed: 2012-06-29
- Assignees: Lixte Biotechnology, Inc.
- Inventors: John S. Kovach
- Web page: https://patentgrep.com/patent/US20150148353A1

## CPC

- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61K 31/34: having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K 31/4178: not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
- A61K 31/4525: containing a five-membered ring with oxygen as a ring hetero atom
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 5/50: for increasing or potentiating the activity of insulin
- C07D 493/08: Bridged systems
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

A method of increasing the insulin sensitivity of a mammalian cell by contacting the cell with a protein phosphatase 2A (PP2A) inhibitor having the structure:

## Claims

### Claim 1

A method of increasing the insulin sensitivity of a mammalian cell by contacting the cell with a protein phosphatase 2A (PP2A) inhibitor having the structure:
wherein
bond α is present or absent;
R1 and R2 is each independently H, O− or OR9,
where R9 is H, alkyl, alkenyl, alkynyl or aryl,
or R1 and R2 together are ═O;
R3 and R4 are each different, and each is OH, O−, OR9,
O(CH2)1-6R9, SH, S−, SR9,
where X is O, S, NR10, or N+R10R10,
where each R10 is independently H, alkyl, C2-C12 alkyl, alkenyl, C4-C12 alkenyl, alkynyl, aryl, substituted aryl where the substituent is other than chloro when R1 and R2 are ═O,
—CH2CN, —CH2CO2R11, —CH2COR11, —NHR11 or —NH+(R11)2,
wherein each R11 is independently alkyl, alkenyl or alkynyl, or H;
R5 and R6 is each independently H, OH, or R5 and R6 taken together are ═O;
R7 and R8 is each independently H, F, Cl, Br, SO2Ph, CO2CH3, or SR12,
where R12 is H, alkyl, alkenyl, alkynyl or aryl; and
each occurrence of alkyl, alkenyl, or alkynyl is branched or unbranched, unsubstituted or substituted,
or a salt, enantiomer or zwitterion of the compound.

### Claim 2 (depends on 1)

The method of claim 1, wherein glucose uptake into the mammalian cell is increased.

### Claim 3 (depends on 1)

The method of claim 1, wherein the glucose concentration surrounding the mammalian cell is decreased.

### Claim 4 (depends on 1)

The method of claim 1, wherein phosphorylation of Akt in the mammalian cell is increased.

### Claim 5 (depends on 1)

The method of claim 1, wherein activation of Akt in the mammalian cell is increased.

### Claim 6 (depends on 1)

The method claim 1, wherein the mammalian cell is a liver, fat, muscle or endothial cell.

### Claim 7 (depends on 1)

The method of claim 1, wherein the protein phosphatase 2A inhibitor has the structure
wherein
bond α is present or absent;
R1 and R2 is each independently H, O− or OR9,
where R9 is H, alkyl, alkenyl, alkynyl or aryl,
or R1 and R2 together are ═O;
R3 and R4 are each different, and each is OH, O−, OR9, SH, S−, SR9,
where X is O, S, NR10, or N+R10R10,
where each R10 is independently H, alkyl, C2-C12 alkyl, alkenyl, C4-C12 alkenyl, alkynyl, aryl, substituted aryl where the substituent is other than chloro when R1 and R2 are ═O,
—CH2CN, —CH2CO2R11, —CH2COR11, —NHR11 or —NH+(R11)2,
where each R11 is independently alkyl, alkenyl alkynyl, or H;
R5 and R6 is each independently H, OH, or R5 and R6 taken together are ═O;
R7 and R8 is each independently H, F, Cl, Br, SO2Ph, CO2CH3, or SR12,
where R12 is H, aryl or a substituted or unsubstituted alkyl, alkenyl or alkynyl; and
each occurrence of alkyl, alkenyl, or alkynyl is branched or unbranched, unsubstituted or substituted,
or a salt, enantiomer or zwitterion of the compound.

### Claim at position 8

8-12. (canceled)

### Claim 13 (depends on 7)

The method of claim 7, wherein
R1 and R2 together are ═O;
R3 is O− or OR9,
where R9 is H, methyl, ethyl or phenyl;
R4 is
where X is O, S, NR10, or N+R10R10,
where each R10 is independently H, alkyl, substituted C2-C12 alkyl, alkenyl, substituted C4-C12 alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl where the substituent is other than chloro,
—CH2CN, —CH2CO2R11, —CH2COR11, —NHR11 or —NH+(R11)2,
where R11 is alkyl, alkenyl or alkynyl, each of which is substituted or unsubstituted, or H;
R5 and R6 taken together are ═O; and
R7 and R8 is each independently H, F, Cl, Br, SO2Ph, CO2CH3, or SR12,
where R12 is a substituted or unsubstituted alkyl, alkenyl or alkynyl.

### Claim at position 10

14-16. (canceled)

### Claim 17 (depends on 13)

The method of claim 13,
wherein R4 is
where R10 is R10 H, alkyl, substituted C2-C12 alkyl, alkenyl, substituted C4-C12 alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl where the substituent is other than chloro when R1 and R2 are ═O,
—CH2CN, —CH2CO2R11, —CH2COR11, —NHR11 or —NH+(R11)2,
where R11 is H or alkyl.

### Claim 18 (depends on 13)

The method of claim 13,
wherein R4 is
or
wherein R4 is
where R10 is
or
wherein R4 is
or
wherein R4 is

### Claim at position 13

19-35. (canceled)

### Claim 36 (depends on 7)

The method of claim 7, wherein the protein phosphatase 2A inhibitor has the structure
wherein
bond α is present or absent;
R9 is present or absent and when present is H, alkyl, alkenyl, alkynyl or phenyl; and
X is O, NR10, or N+R10R10,
where each R10 is indepdently H, alkyl, substituted C2-C12 alkyl, alkenyl, substituted C4-C12 alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl where the substituent is other than chloro,
—CH2CN, —CH2CO2R12, or —CH2COR12,
where R12 is H or alkyl,
or a salt, zwitterion, or enantiomer of the compound.

### Claim 37 (depends on 36)

The method of claim 36, where in the protein phosphatase 2A inhibitor has the structure
wherein
bond α is present or absent;
X is O or NH+R10,
where R10 is H, alkyl, substituted C2-C12 alkyl, alkenyl, substituted C4-C12 alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl where the substituent is other than chloro,
—CH2CN, —CH2CO2R12, or —CH2COR12,
where R12 is H or alkyl.

### Claim 38

(canceled)

### Claim 39

(canceled)

### Claim 40 (depends on 7)

The method of claim 7, wherein the protein phosphatase 2A inhibitor has the structure

### Claim 41 (depends on 7)

The method of claim 7, wherein the protein phosphatase 2A inhibitor has the structure

### Claim 42 (depends on 36)

The method of claim 36, wherein the protein phosphatase 2A inhibitor has the structure
wherein
bond α is present or absent; X is NH+R10,
where R10 is present or absent and when present R10 is alkyl, substituted C2-C12 alkyl, alkenyl, substituted C4-C12 alkenyl,
—CH2CN, —CH2CO2R12, or —CH2COR12,
where R12 is H or alkyl.

### Claim 43

(canceled)

### Claim 44 (depends on 7)

The method of claim 7, wherein the protein phosphatase 2A inhibitor has the structure
wherein
bond α is present or absent;
R1 and R2 is each independently H, O− or OR9,
where R9 is H, alkyl, alkenyl, alkynyl or aryl,
or R1 and R2 together are ═O;
R3 and R4 are each different, and each is O(CH2)1-6R9 or OR9, or
where X is O, S, NR10, or N+R10R10,
where each R10 is independently H, alkyl, hydroxyalkyl, C2-C12 alkyl, alkenyl, C4-C12 alkenyl, alkynyl, aryl, where the substituent is other than chloro when R1 and R2 are ═O,
—CH2CN, —CH2CO2R11, —CH2COR11, —NHR11 or —NH+(R11)2, where each R11 is independently H, alkyl, alkenyl, or alkynyl;
or R3 and R4 are each different and each is OH or
R5 and RE is each independently H, OH, or R5 and R6 taken together are ═O;
R7 and R5 is each independently H, F, Cl, Br, SO2Ph, CO2CH3, or SR12,
where R12 is H, aryl or a substituted or unsubstituted alkyl, alkenyl or alkynyl; and
each occurrence of alkyl, alkenyl, or alkynyl is branched or unbranched, unsubstituted or substituted,
or a salt, enantiomer or zwitterion of the compound.

### Claim at position 23

45-50. (canceled)

### Claim 51 (depends on 44)

The method of claim 44,
wherein
R1 and R2 together are ═O;
R3 is OH, O(CH2)R9, or OR9,
where R9 is phenyl or CH2CCl3,
R4 is
where R10 is CH3 or CH3CH2OH;
R5 and R6 together are ═O; and
R7 and R8 are each independently H.

### Claim at position 25

52-58. (canceled)

### Claim 59 (depends on 44)

The method of claim 44, wherein the protein phosphatase 2A inhibitor has the structure

### Claim 60

(canceled)

### Claim 61

A method of treating Type 2 Diabetes in a subject afflicted with Type 2 Diabetes comprising administering to the subject a therapeutically effective amount of a protein phosphatase 2A inhibitor having the structure:
wherein
bond α is present or absent;
R1 and R2 is each independently H, O− or OR9,
where R9 is H, alkyl, alkenyl, alkynyl or aryl,
or R1 and R2 together are ═O;
R3 and R4 are each different, and each is OH, O−, OR9, OR10,
O(CH2)1-6R9, SH, S−, SR9,
where X is O, S, NR10, or N+R10R10,
where each R10 is independently H, alkyl, C2-C12 alkyl, alkenyl, C4-C12 alkenyl, alkynyl, aryl, substituted aryl where the substituent is other than chloro when R1 and R2 are ═O,
—CH2CN, —CH2CO2R11, —CH2COR11, —NHR11 or —NH+(R11)2,
wherein each R11 is independently alkyl, alkenyl or alkynyl, or H;
R5 and R6 is each independently H, OH, or R5 and R6 taken together are ═O;
R7 and R8 is each independently H, F, Cl, Br, SO2Ph, CO2CH3, or SR12,
where R12 is H, alkyl, alkenyl, alkynyl or aryl; and
each occurrence of alkyl, alkenyl, or alkynyl is branched or unbranched, unsubstituted or substituted,
or a salt, enantiomer or zwitterion of the compound.

### Claim 62

A method of reducing complications associated with Type 2 Diabetes in a subject afflicted with Type 2 Diabetes comprising administering to the subject a therapeutically effective amount of a protein phosphatase 2A inhibitor having the structure:
wherein
bond α is present or absent;
R1 and R2 is each independently H, O− or OR9,
where R9 is H, alkyl, alkenyl, alkynyl or aryl,
or R1 and R2 together are ═O;
R3 and R4 are each different, and each is OH, O−, OR9, OR10,
O(CH2)1-6R9, SH, S−, SR9,
where X is O, S, NR10, or N+R10R10,
where each R10 is independently H, alkyl, C2-C12 alkyl, alkenyl, C4-C12 alkenyl, alkynyl, aryl, substituted aryl where the substituent is other than chloro when R1 and R2 are ═O,
—CH2CN, —CH2CO2R11, —CH2COR11, —NHR11 or —NH+(R11)2,
wherein each R11 is independently alkyl, alkenyl or alkynyl, or H;
R5 and R6 is each independently H, OH, or R5 and R6 taken together are ═O;
R7 and R8 is each independently H, F, Cl, Br, SO2Ph, CO2CH3, or SR12,
where R12 is H, alkyl, alkenyl, alkynyl or aryl; and
each occurrence of alkyl, alkenyl, or alkynyl is branched or unbranched, unsubstituted or substituted,
or a salt, enantiomer or zwitterion of the compound.
